Fundraising FoxAisling Capital — 2021 Investments
5 investments dated 2021 · listed companies and verified rows first · show all
Summus Global provides doctor-led clinical navigation and virtual access to specialists across 120+ medical specialties, offering members personalized guidance, second opinions, in-network recommendations, and condition-specific support programs.
Digital HealthHealthtechWellness & FitnessNew York, US
Julian Flannery(Executive Officer, Director)in
BoardRick Buhrman(Director)Dennis Purcell(Executive Officer)inAftab Kherani(Director)Scott Harrison(Director)
Board seatAyman Sabi· per SEC Form D · $16M raise · filed Apr 2021
Co-investorsOutsidersTeamworthy Ventures
Antios Therapeutics develops antiviral therapies for hepatitis B virus (HBV) and other viral diseases, including its Active Site Polymerase Inhibitor Nucleotide (ASPIN) ATI-2173 and a capsid assembly modulator program.
BiotechHealthtechMendham, US
Gregory Mayes(Executive Officer, Director)Douglas Mayers(Executive Officer)inTamra Adams(Executive Officer)inAbel De La Rosa(Director)
BoardIyona Rajkomar(Director)inBenjamin Rovinski(Director)
Co-investorsAltium CapitalAvego BioScience CapitalLifeSci Venture PartnersPontifax Venture CapitalAmzak HealthDelos Capital+8 more
Irvine, US
Sanjay Rajpoot(Executive Officer, Director)
Developing off-the-shelf hematopoietic stem cell therapies for severe diseases.
Co-investorsOrbiMedNorthpond Ventures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Cellevolve
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.